Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Emily Horn

GlaxoSmithKline

United States

Research Interests

Explore related searches

Articles (15)

Collaborators (4)

J. Bradley Layton

Health Solutions

UNITED STATES

David Singer

GlaxoSmithKline

UNITED STATES

Meryem Bektas

Health Solutions

UNITED STATES

Shahnaz Khan

Health Solutions

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Emily Horn

Research Interests

Explore related searches

Articles (15)

Collaborators (4)

J. Bradley Layton

David Singer

Meryem Bektas

Shahnaz Khan

Make your next move.

Emily Horn

Research Interests

Explore related searches

Articles (15)

Real-world effectiveness of adjuvanted RSVPreF3 vaccination in the prevention of RSV-related hospitalization among US adults aged ≥60 years

Effectiveness of the adjuvanted respiratory syncytial virus prefusion f3 vaccine in preventing major adverse cardiovascular events and severe exacerbations of copd and asthma among US adults ≥ 60 years of age

Disparities in Respiratory Syncytial Virus Risk Factors, Diagnosis, and Outcomes in Adults by Race, Ethnicity, and Other Social Determinants of Health in the United States

RSV Testing Patterns and Characteristics Associated with RSV Testing Among Adults Aged 50 Years or Older in the United States

Prevalence and Age at Diagnosis of Risk Factors for Severe Respiratory Syncytial Virus Disease Among US Adults: An Analysis of 2011–2020 NHANES Data

The Burden of Hepatitis A Outbreaks in the United States: Health Outcomes, Economic Costs, and Management Strategies

Nurse Practitioners’ Knowledge, Attitudes, and Practices Surrounding Adult Hepatitis Vaccination

Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States

Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies

A Response to: Letter to the Editor Regarding “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”

Response to Gomez et al.’s Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”

The broader impacts of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate vaccines

Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants

Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India

Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age

Collaborators (4)

J. Bradley Layton

David Singer

Meryem Bektas

Shahnaz Khan

Make your next move.